|
|
|
|
|
| Teixeira,A.M.S.; Plavnik,F.L.; Fernandes,F.B.; Marson,O.; Christofalo,D.M.J.; Ajzen,S.A.; Sesso,R.; Franco,M.C.; Casarini,D.E.. |
| We described angiotensin-I-converting enzyme (ACE) isoforms with molecular masses of 190, 90, and 65 kDa in the urine of normotensive offspring of hypertensive subjects. Since they did not appear in equal amounts, we suggested that 90 kDa ACE might be a marker for hypertension. We evaluated the endothelial response in normotensive offspring with or without family history of hypertension and its association with the 90 kDa ACE in urine. Thirty-five normotensive subjects with a known family history of hypertension and 20 subjects without a family history of hypertension, matched for age, sex, body weight, and blood pressure, were included in the study. Endothelial function was assessed by ultrasound and a sample of urine was collected for determination of... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Endothelial dysfunction; Angiotensin-I-converting enzyme; Hypertension; Normotension; N-domain angiotensin- converting enzyme. |
| Ano: 2008 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2008000500002 |
| |
|
|
| Santuzzi,C.H.; Tiradentes,R.V.; Mengal,V.; Claudio,E.R.G.; Mauad,H.; Gouvea,S.A.; Abreu,G.R.. |
| Angiotensin II is a key player in the pathogenesis of renovascular hypertension, a condition associated with endothelial dysfunction. We investigated aliskiren (ALSK) and L-arginine treatment both alone and in combination on blood pressure (BP), and vascular reactivity in aortic rings. Hypertension was induced in 40 male Wistar rats by clipping the left renal artery. Animals were divided into Sham, 2-kidney, 1-clip (2K1C) hypertension, 2K1C+ALSK (ALSK), 2K1C+L-arginine (L-arg), and 2K1C+ALSK+L-arginine (ALSK+L-arg) treatment groups. For 4 weeks, BP was monitored and endothelium-dependent and independent vasoconstriction and relaxation were assessed in aortic rings. ALSK+L-arg reduced BP and the contractile response to phenylephrine and improved... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: 2K1C hypertension; Endothelial dysfunction; Aliskiren; L-arginine; RAAS and oxidative stress. |
| Ano: 2015 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2015000100065 |
| |
|
|
| Davel,A.P.; Wenceslau,C.F.; Akamine,E.H.; Xavier,F.E.; Couto,G.K.; Oliveira,H.T.; Rossoni,L.V.. |
| The endothelium plays a vital role in maintaining circulatory homeostasis by the release of relaxing and contracting factors. Any change in this balance may result in a process known as endothelial dysfunction that leads to impaired control of vascular tone and contributes to the pathogenesis of some cardiovascular and endocrine/metabolic diseases. Reduced endothelium-derived nitric oxide (NO) bioavailability and increased production of thromboxane A2, prostaglandin H2 and superoxide anion in conductance and resistance arteries are commonly associated with endothelial dysfunction in hypertensive, diabetic and obese animals, resulting in reduced endothelium-dependent vasodilatation and in increased vasoconstrictor responses. In addition, recent studies have... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Endothelial dysfunction; Hypertension; Sympathetic hyperactivity; Diabetes; Obesity. |
| Ano: 2011 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2011000900014 |
| |
|
| |
|
|
| Lobato,N.S.; Filgueira,F.P.; Akamine,E.H.; Tostes,R.C.; Carvalho,M.H.C.; Fortes,Z.B.. |
| Obesity is strongly associated with high blood pressure, dyslipidemia, and type 2 diabetes. These conditions synergistically increase the risk of cardiovascular events. A number of central and peripheral abnormalities can explain the development or maintenance of high blood pressure in obesity. Of great interest is endothelial dysfunction, considered to be a primary risk factor in the development of hypertension. Additional mechanisms also related to endothelial dysfunction have been proposed to mediate the development of hypertension in obese individuals. These include: increase in both peripheral vasoconstriction and renal tubular sodium reabsorption, increased sympathetic activity and overactivation of both the renin-angiotensin system and the... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Hypertension; Obesity; Endothelial dysfunction; Oxidative stress; Renin-angiotensin system; Nitric oxide. |
| Ano: 2012 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2012000500003 |
| |
|
|
| Lopes,A.A.; Barreto,A.C.; Maeda,N.Y.; Cícero,C.; Soares,R.P.S.; Bydlowski,S.P.; Rich,S.. |
| Biomarkers have been identified for pulmonary arterial hypertension, but are less well defined for specific etiologies such as congenital heart disease-associated pulmonary arterial hypertension (CHDPAH). We measured plasma levels of eight microvascular dysfunction markers in CHDPAH, and tested for associations with survival. A cohort of 46 inoperable CHDPAH patients (age 15.0 to 60.2 years, median 33.5 years, female:male 29:17) was prospectively followed for 0.7 to 4.0 years (median 3.6 years). Plasma levels of von Willebrand factor antigen (VWF:Ag), tissue plasminogen activator (t-PA) and its inhibitor (PAI-1), P-selectin, reactive C-protein, tumor necrosis factor alpha, and interleukin-6 and -10 were measured at baseline, and at 30, 90, and 180 days in... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Pulmonary hypertension; Congenital heart disease; Eisenmenger syndrome; Endothelial dysfunction; Von Willebrand factor; Th2 cytokine response. |
| Ano: 2011 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2011001200011 |
| |
|
| |
|
|
| Barreto,A.C.; Maeda,N.Y.; Soares,R.P.S.; Cícero,C.; Lopes,A.A.. |
| We investigated whether chronic rosuvastatin administration could improve the abnormalities of the circulating levels of vascular dysfunction markers in pulmonary arterial hypertension (PAH). Sixty patients, aged 13 to 60 years, with idiopathic (N = 14) or congenital heart disease-associated PAH (N = 46) were equally but randomly assigned to rosuvastatin treatment (10 mg a day, orally) or placebo for 6 months in a blind fashion. Plasma levels of P-selectin, tissue-plasminogen activator and its inhibitor as well as von Willebrand factor antigen were measured by enzyme-linked immunoassay before and after 1, 3, and 6 months of treatment. Baseline levels of biomarkers were elevated (68, 16, 45 and 46% increase relative to controls, for P-selectin, von... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Pulmonary hypertension; Statins; Endothelial dysfunction; P-selectin; Tissue-plasminogen activator and inhibitor; Von Willebrand factor. |
| Ano: 2008 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2008000800003 |
| |
|
|
|
